Friday, July 1, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Heightened antibody responses in COVID-19 booster vaccinated individuals following SARS-CoV-2 Omicron

by Medical Finance
in Coronavirus
Study: Antibody responses to known and unknown SARS-CoV-2 infections after mRNA vaccine booster. Image Credit: Wachiwit/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent article posted to the medRxiv* preprint server, investigators illustrated that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection post-booster vaccination can impart robust, long-lasting immunity against future re-infections.

Study: Antibody responses to known and unknown SARS-CoV-2 infections after mRNA vaccine booster. Image Credit: Wachiwit/Shutterstock
Study: Antibody responses to known and unknown SARS-CoV-2 infections after mRNA vaccine booster. Image Credit: Wachiwit/Shutterstock

Background

Studies have reported that SARS-CoV-2 vaccines produce robust antibody- and cellular-mediated immune responses that impart durable protection against severe Coronavirus disease 2019 (COVID-19). Nevertheless, COVID-19 and its vaccination-induced neutralizing antibody levels diminish with time, and antigenic alterations in novel SARS-CoV-2 variants limit antibody-mediated neutralization’s efficacy, increasing breakthrough infections, a large percentage of which are mild. 

This dynamic has unfolded significantly with the SARS-CoV-2 Omicron (B.1.1.529) mutation, the most recent viral variant to spread across the United States (US) starting in late 2021 and culminating in January 2022, exhibiting the highest daily case rates documented since the pandemic began. According to the Centers for Disease Control and Prevention (CDC), 57.7% of the US population displayed serological proof of natural SARS-CoV-2 infection by late February 2022.

About the study

In the present study, the scientists assessed the antibody response to natural COVID-19 during the SARS-CoV-2 Omicron wave and the antibody response to booster messenger ribonucleic acid (mRNA) vaccine doses. From September 2021 to March 2022, the researchers monitored a fully vaccinated community group encompassing 41 subjects without past SARS-CoV-2 infection diagnoses through the Omicron wave after a booster dose of an mRNA vaccine.

The researchers recruited a group of adults with fully vaccinated status (two doses of SARS-CoV-2 Moderna or Pfizer vaccine), no past clinically confirmed COVID-19 infection, and an interest in receiving a third booster dose in Chicago before the emergence of the Omicron variant. The follow-up phase of the study overlapped with the emergence of the Omicron strain, which was initially identified in the Chicagoland region on December 7, 2021, and swiftly became the dominant variant, with infections diminishing in February 2022. The authors estimated the extent of antibody response to the booster vaccination and the pace of decline with time using blood sampling before and one week after the booster dosing and follow-up sampling for about four months in the peak of the Omicron wave.

Additionally, the team identified immune reactions caused by the SARS-CoV-2 infection rather than the vaccination by quantifying antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein. Further, they assessed prior COVID-19 by detecting anti-N, even if subjects were asymptomatic or did not test positive for SARS-CoV-2 in at-home or clinical testing. As a result, the study calculated the prevalence of COVID-19 following a booster vaccination during the Omicron wave. In addition, the antibody response to booster vaccination with and without successive SARS-CoV-2 infection was examined.

Findings

The study results demonstrated that anti-SARS-CoV-2 spike (S) immunoglobulin G (IgG) concentrations recognizing the Delta, Omicron, and wildtype variants increased 9.2 to 16.2-time one week after the COVID-19 booster dose; yet they dropped over the next four months. While COVID-19 vaccines were significantly efficient at averting severe illness, the present serological findings showed that infections after a booster dose were more prevalent than diagnostic testing suggested. In the current cohort of the recently booster-vaccinated subjects, one out of every five had known COVID-19 infection based on a SARS-CoV-2-positive diagnostic test.

Indeed, 19.5% of subjects reported a known incidence of COVID-19 during the SARS-CoV-2 Omicron wave, which was verified by anti-N IgG. At the same time, another 36.5% developed anti-N IgG after the booster dose, attributed to an asymptomatic, unknown SARS-CoV-2 infection. Thus, 56% of subjects generated anti-N antibodies, confirming COVID-19, by the conclusion of the follow-up timeframe.

At 120 days following the booster vaccination, COVID-19 characterized by anti-N IgG, whether known or unknown to the subject, raised anti-S IgG levels 2.5 to 4.7-fold compared to individuals without serological proof of SARS-CoV-2 infection. In addition, anti-S antibody levels were comparable in the unknown and known SARS-CoV-2-positive cohorts at the end of the follow-up term.

Conclusions

According to the authors, this was the initial study to depict that Omicron infections post-COVID-19 booster vaccination heighten SARS-CoV-2 antibody concentrations beyond what was seen with only a booster vaccination in both unknown and known infection groups.

In the current prospective cohort investigation, the authors documented a high incidence of SARS-CoV-2 Omicron infection after the COVID-19 booster dose, with both unknown and self-reported symptomatic infections centered on anti-N seropositivity among both cohorts. The present study demonstrated Omicron’s increased transmissibility and the value of anti-N antibody tests in determining the prevalence of COVID-19.

The authors found that symptomatic COVID-19 was not required for a substantial antibody response among vaccinated/booster-vaccinated people. Moreover, Omicron infection following a booster vaccination might result in better or long-lasting antibody-facilitated immunity towards future SARS-CoV-2 re-infection. Nonetheless, the anti-S IgG response to Omicron was much lower than other SARS-CoV-2 variants, and the pace of decline was rapid, suggesting a poorer level of immunity towards variants of this lineage.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance. Image Credit: G.Tbov/Shutterstock

First cases of co-infection with Delta and Omicron identified during local co-circulation of both SARS-CoV-2 lineages

by Medical Finance
June 30, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers revealed the co-infection of the severe acute respiratory syndrome...

Study: Trends in non-COVID-19 hospitalizations prior to and during the COVID-19 pandemic period, United States, 2017 – 2021. Image Credit: Gorodenkoff/Shutterstock

Exploring changes in non-COVID-19 hospitalization rates before and during COVID-19

by Medical Finance
June 30, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers assessed the trends in non-coronavirus disease 2019 (COVID-19) hospitalizations...

Study: Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. Image Credit: Kateryna Kon/Shutterstock

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, a team of researchers examined the memory B cell repertoire...

Study: P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants. Image Credit: Lightspring/Shutterstock

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the importance of the P681 residue within the...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

5 things you should know about ‘free’ at-home covid tests

by Medical Finance
June 30, 2022
0

Americans keep hearing that it is important to test frequently for covid-19 at home. But just try to find an...

Study: COVID-19 onset reduced the sex ratio at birth in South Africa. Image Credit: Paulo Vilela/Shutterstock

Reduction in the sex ratio at birth found following the COVID-19 pandemic

by Medical Finance
June 30, 2022
0

The sex ratio at birth (SRB) has been defined as male/(male+female) live births. SRB, at the population level in South...

Next Post
NPS

Tackling the Global Issue of New Psychoactive Substances

How Did We Get Here, Where are We Going?

How Did We Get Here, Where are We Going?

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Nasopharyngeal Microbiota Profiling of Pregnant Women With Sars-Cov-2 Infection. Image Credit: NIAID
    Study shows SARS-CoV-2 infection can change nasopharyngeal microbiota composition in pregnancy
  • Study: COVID-19 vaccination breakthrough infections in a real-world setting: Using community reporters to evaluate vaccine effectiveness. Image Credit: Srarn Artrattanakul / Shutterstock.com
    COVID-19 vaccination breakthrough infections in a real-world setting
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply